PLIANT THERAPEUTICS, INC. PLRX
We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β). We have applied our deep understanding of integrin biology, along with our medicinal chemistry and translational medicine expertise to develop a proprietary drug discovery platform that we believe has broad applicability across multiple areas of disease.
Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in development for the treatment of solid tumors. In 2025, we announced positive data from a Phase 1 open-label dose-escalation trial of PLN-101095 as monotherapy and in combination with the immunotherapy pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. We also continue to explore the full potential of our drug discovery platform consisting of a proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M | $41.8M | $57.1M | — |
| R&D | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M | $66.2M | $47.4M | — |
| SG&A | $47.2M | $59.1M | $57.9M | $39.9M | $27.6M | $17.3M | $10.9M | — |
| Total operating expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M | $83.5M | $58.3M | — |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M | -$41.6M | -$1.2M | — |
| Interest expense | $2.6M | $3.0M | $1.3M | $791.0K | $0 | — | — | — |
| Pre-tax income | $149.3M | $210.3M | $161.3M | -$123.3M | -$97.3M | -$41.5M | -$631.0K | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | $149.3M | $210.3M | $161.3M | -$123.3M | -$97.3M | -$41.5M | -$631.0K | — |
| EPS, basic | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 | — |
| EPS, diluted | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 | — |
| Shares, diluted (wtd. avg.) | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M | 1.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.4M | $71.2M | $64.7M | $33.7M | $51.7M | $50.9M | $85.8M | $60.9M |
| Short-term investments | $145.5M | $284.5M | $431.0M | $297.5M | $148.9M | $226.0M | $17.0M | — |
| Receivables | — | — | $0 | $2.0M | $2.0M | $9.3M | $7.1M | — |
| Total current assets | $196.4M | $362.3M | $505.5M | $340.3M | $209.4M | $290.8M | $111.9M | — |
| Property, plant and equipment | $2.9M | $5.5M | $3.6M | $4.5M | $4.6M | $4.3M | $4.1M | — |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M | $295.5M | $119.1M | — |
| Accounts payable | $480.0K | $6.0M | $4.5M | $1.6M | $3.0M | $2.0M | $1.2M | — |
| Total current liabilities | $16.4M | $33.2M | $28.5M | $23.9M | $16.8M | $11.6M | $8.2M | — |
| Long-term debt | $0 | $30.2M | $10.1M | $9.9M | $0 | — | — | — |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M | $12.5M | $9.1M | — |
| Retained earnings | -$859.4M | -$710.1M | -$499.7M | -$338.4M | -$215.1M | -$117.8M | -$76.3M | — |
| Total equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M | $283.1M | -$76.3M | -$71.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M | -$37.3M | -$2.8M | — |
| Depreciation and amortisation | $1.7M | $2.1M | $1.8M | $1.8M | $1.5M | $1.3M | $1.1M | — |
| Stock-based compensation | $26.2M | $37.6M | $44.5M | $22.6M | $10.4M | $3.9M | $1.8M | — |
| Capital expenditure | $374.0K | $3.8M | $921.0K | $1.8M | $2.0M | $1.5M | $964.0K | — |
| Investing cash flow | $134.3M | $140.3M | -$127.0M | -$150.2M | $73.7M | -$210.9M | -$17.9M | — |
| Financing cash flow | -$31.7M | $23.1M | $274.4M | $226.9M | $2.5M | $213.2M | $45.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001746473-26-000076.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $57.1M | $41.8M | $7.6M | $9.7M | $1.6M | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$631.0K | -$41.5M | -$97.3M | -$123.3M | $161.3M | $210.3M | $149.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Officer or director change Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |